Clinical impact of pharmacokinetics and pharmacodynamics (PK/PD) in 2005
17th ISAP symposium held within meetings of other Scientific Societies  
held during and in cooperation with the 24th International Congress of Chemotherapy (ICC)
Manilla, Philippines, June 5th, 2005  - 1:30-3:00 pm

Convener:
Paul M. Tulkens, MD, PhD Catholic University of Louvain, Brussels, Belgium

The symposium presented a mini "state of the art" of pharmacodynamic/pharmacokinetics followed by 4 tyoical examples  of how as it can be used, today, by clinicians in specific indications with the following objectives: 


Banaue Rice Terraces

  • The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place ?
    WEBPDF

    Paul M. Tulkens (Cellular and Molecula Pharmacology, Catholic University of Louvain, Brussels, Belgium)
  • Clinical implication 1: dose adjustments and ensuring efficacy in urinary tract infections
    WEB
    - PDF
    Kurt Naber (Department of Urology, Hospital St. Elisabeth, Straubing, Germany.
  • Clinical implication 2: dose adjustments and fighting the emergence of resistance in pneumococci
    WEB
    - PDF
    Donald E. Low  (Department of Microbiology, Mount Sinai Hospital, Toronto, Canada)
  • Clinical implication 3: Can and when should beta-lactams be given by continuous infusion ?
    John Turnidge (Department of Microbiology and Infectious Diseases, Women's and Children's Hospital,
    North Adelaide, Australia.)
    WEB - PDF
  • Clinical implication 4: PK/PD as new approach in the treatment of Malaria : the Philippine experience.
    Dorina Bustos (Research Institute for Tropical Medicine, Department of Health, Alabang, Muntinlupa City, Philippines
    WEB - PDF


Useful links
ISAP Home page of ISAP ICC
International Society of Chemotherapy
ICC 
24th International Congress of Chemotherapy (ICC)






Last update: June 28th,  2005



Back to ISAP home page

Credits
Back to ISAP home page